Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Accounts Payables (2022 - 2025)

Coya Therapeutics' Accounts Payables history spans 4 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Accounts Payables rose 230.15% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.1 million, up 230.15%, while the annual FY2024 figure was $1.6 million, 37.42% up from the prior year.
  • Accounts Payables for Q3 2025 was $1.1 million at Coya Therapeutics, up from $931344.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $1.9 million in Q2 2024 and bottomed at $237579.0 in Q2 2023.
  • The 4-year median for Accounts Payables is $1.1 million (2023), against an average of $1.1 million.
  • The largest annual shift saw Accounts Payables soared 692.61% in 2024 before it crashed 50.54% in 2025.
  • A 4-year view of Accounts Payables shows it stood at $1.8 million in 2022, then crashed by 36.34% to $1.2 million in 2023, then skyrocketed by 37.42% to $1.6 million in 2024, then fell by 30.0% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Accounts Payables are $1.1 million (Q3 2025), $931344.0 (Q2 2025), and $1.7 million (Q1 2025).